Affimed to Report First Quarter 2024 Financial Results & Corporate Update on June 12, 2024GlobeNewsWire • 06/05/24
Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant CohortGlobeNewsWire • 06/01/24
Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung CancerGlobeNewsWire • 05/29/24
Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024GlobeNewsWire • 05/23/24
Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 CongressGlobeNewsWire • 05/14/24
Wall Street Analysts Believe Affimed N.V. (AFMD) Could Rally 146.73%: Here's is How to TradeZacks Investment Research • 04/24/24
Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical OncologyGlobeNewsWire • 04/24/24
Affimed N.V. (AFMD) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 04/17/24
Does Affimed N.V. (AFMD) Have the Potential to Rally 263.36% as Wall Street Analysts Expect?Zacks Investment Research • 04/04/24
Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024GlobeNewsWire • 03/21/24
Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung CancerGlobeNewsWire • 01/08/24